Nanologica Q2 2023: Initial comment

Research Note



Redeye has a largely neutral take on Nanologica’s Q2 2023 report in terms of the financials. Sales came in below our estimates, but concrete orders materializing remains key for the investment case. We leave our initial comments.


Filip Einarsson

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.